Neuralink is an American neurotechnology company founded in 2016 by Elon Musk, with headquarters in Fremont, California. The company develops implantable brain-computer interfaces (BCIs) and is focused on creating high-bandwidth neural interfaces to treat neurological conditions and ultimately achieve human-AI symbiosis.
| Attribute |
Details |
| Headquarters |
Fremont, California, USA |
| Founded |
2016 |
| Founder |
Elon Musk |
| CEO |
Elon Musk |
| Employees |
~300+ |
| Funding |
~80 million |
Neuralink's flagship product is the N1 implantable brain-computer interface:
- Electrode Count: 1,024 electrodes across 64 threads
- Thread Diameter: 5 microns (human hair is ~75 microns)
- Wireless: Fully implantable, wireless data transmission
- Battery: Rechargeable inductive charging
- Size: Coin-sized implant
The Link is the subcutaneous receiver that:
- Processes neural signals from the electrode threads
- Wireless transmits data to external devices
- Recharges via inductive charging
- Contains the electronics for signal amplification and digitization
Neuralink developed a custom surgical robot (R1) to implant the threads:
- Precise insertion of micro-electrodes
- Avoids blood vessels during insertion
- Minimizes tissue damage
- Fully automated placement procedure
Neuralink's first-in-human clinical trial is called PRIME (Precise Robotically Implanted Brain-Computer Interface):
- Identifier: NCT05126784
- Status: Recruiting
- Target: Patients with quadriplegia due to spinal cord injury or ALS
- Primary Endpoint: Safety and device functionality
In January 2025, Neuralink announced successful implantation of the N1 device in their first human patient:
- Patient demonstrated ability to control computer cursor using neural signals
- Successfully played chess and interacted with software
- Demonstrated high-accuracy motor intent decoding (>90%)
- No serious adverse events reported in initial cohort
Neuralink has implanted devices in additional patients as part of the PRIME study, expanding clinical experience with the technology.
- Quadriplegia: Enable patients with spinal cord injuries to control computers and devices
- ALS: Restore communication abilities for patients with late-stage ALS
- Blindness: Blindsight program for visual cortex stimulation
- Human-AI Symbiosis: Musk's stated long-term goal is to enable humans to interface with AI
- Memory Augmentation: Potential for cognitive enhancement in Alzheimer's disease
- Treatment of Neurological Conditions: Depression, addiction, PTSD (speculative)
¶ Competitive Landscape
Neuralink competes with other BCI companies:
| Company |
Technology |
Status |
| Blackrock Neurotech |
Utah Array |
FDA Approved |
| Synchron |
Stentrode |
FDA IDE approved |
| Paradromics |
High-density array |
Clinical trials |
| Precision Neuroscience |
Layer 7 array |
Preclinical |
- FDA Breakthrough Device Designation: Granted for the N1 device
- FDA Approval for Human Trials: PRIME study approved
- Human Trials: Ongoing (2025-present)
- Highest Channel Count: 1,024 electrodes vs. ~100-300 for competitors
- Wireless: Fully implantable with no percutaneous connections
- Flexible Threads: Reduce tissue damage and immune response
- Robotic Implantation: Precise, consistent placement
- Advanced Signal Processing: Machine learning for neural decoding
- Long-term Safety: Limited long-term data on implant safety
- Durability: Questions about device longevity
- Manufacturing: Scaling production of complex devices
- Cost: Currently extremely expensive
-
Musk et al. Neuralink: An integrated brain-machine interface. Journal of Neural Engineering. 2022.
-
Neuralink has published preprint papers on electrode design and surgical techniques, though peer-reviewed clinical data is still emerging.
- Blackrock Neurotech - Competing BCI company
- Synchron - Competing BCI company
- Paradromics - Competing BCI company
- Brain-Computer Interface Technology Landscape
- BCI Company Comparison Matrix
- Motor Cortex